4//SEC Filing
Poddar Richa 4
Accession 0001439222-22-000020
CIK 0001439222other
Filed
Feb 22, 7:00 PM ET
Accepted
Feb 23, 4:11 PM ET
Size
12.3 KB
Accession
0001439222-22-000020
Insider Transaction Report
Form 4
Poddar Richa
Chief Commercial Officer
Transactions
- Exercise/Conversion
Common stock
2022-02-18+1,884→ 4,525 total - Exercise/Conversion
Performance share units
2022-02-18−1,884→ 1,883 total→ Common stock (1,884 underlying) - Tax Payment
Common stock
2022-02-22$29.08/sh−742$21,577→ 4,441 total - Exercise/Conversion
Common stock
2022-02-22+658→ 5,183 total - Exercise/Conversion
Restricted stock units
2022-02-22−658→ 0 total→ Common stock (658 underlying)
Footnotes (4)
- [F1]Each performance share unit represents a contingent right to receive one share of the issuer's common stock.
- [F2]The PSUs vest as to one-third of the underlying shares of common stock, upon the achievement of each of three specified research, regulatory and commercial milestones, subject to continued service. The performance criteria for the specified regulatory milestone was determined to have been met on February 18, 2022, resulting in the vesting of the PSUs as to one-third of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
- [F3]Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- [F4]The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments.
Documents
Issuer
AGIOS PHARMACEUTICALS, INC.
CIK 0001439222
Entity typeother
Related Parties
1- filerCIK 0001897274
Filing Metadata
- Form type
- 4
- Filed
- Feb 22, 7:00 PM ET
- Accepted
- Feb 23, 4:11 PM ET
- Size
- 12.3 KB